MEDA PHARMA S.P.A. - risultati della ricerca

Unione Europea - italiano - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustina - hodgkin disease; lymphoma, non-hodgkin - agenti antineoplastici - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

diclofenac meda dolo compresse effervescenti

meda pharma gmbh - diclofenacum natricum - compresse effervescenti - diclofenacum natricum 25 mg, acidum adipinicum, acidum citricum, natrii docusas, lactosum 229.6 mg, maltodextrinum, natrii carbonas, natrii citras dihydricus, natrii hydrogenocarbonas, povidonum k 25, propylenglycolum, sorbitolum 20 mg, aromatica (kirschen), aspartamum 5 mg, natrii cyclamas, pro compresso corresp. natrium 151.43 mg. - antireumatici, antiphlogistikum, analgesico - synthetika